American Century Companies’s ADC Therapeutics ADCT Stock Holding History

American Century Companies’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-451,637	Closed	-$2.18M	–	2578
2022 Q3	$2.18M	Sell	451,637 -190	-0%	-$1.38K	﹤0.01%	1414
2022 Q2	$3.59M	Buy	451,827 +30,530	+7%	+$289K	﹤0.01%	1230
2022 Q1	$6.19M	Buy	421,297 +123	+0%	+$1.95K	﹤0.01%	1053
2021 Q4	$8.51M	Buy	421,174 +41,426	+11%	+$999K	0.01%	934
2021 Q3	$10.3M	Sell	379,748 -301	-0.1%	-$7.71K	0.01%	841
2021 Q2	$9.25M	Buy	380,049 +912	+0.2%	+$21.2K	0.01%	836
2021 Q1	$9.26M	Buy	379,137 +39,048	+11%	+$1.13M	0.01%	794
2020 Q4	$10.9M	Buy	340,089 +74,951	+28%	+$2.46M	0.01%	744
2020 Q3	$8.75M	Buy	+265,138	New	+$11.5M	0.01%	733

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

American Century Companies's ADCT Position: Q4 2022 in Review

American Century Companies sold out of ADC Therapeutics (ADCT) in Q4 2022, closing a stake of 451,637 shares — an estimated $2.18M sold.

American Century Companies first reported a position in ADCT in Q3 2020 and held it in 9 quarters. The position peaked at $10.9M in Q4 2020. 60 funds tracked by Wall St. Rank hold ADCT as of Q4 2022.

American Century Companies reported no remaining ADC Therapeutics position as of Q4 2022 after selling out during the quarter.
American Century Companies sold 451,637 ADC Therapeutics shares in Q4 2022, an estimated $2.18M.
American Century Companies first reported a position in ADC Therapeutics in Q3 2020 and held it in 9 quarters.
American Century Companies's ADC Therapeutics position peaked at $10.9M in Q4 2020.
60 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2022.

Based on American Century Companies's 13F filing for Q4 2022, filed 13 Feb 2023.